NCT05929807View on ClinicalTrials.gov

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

January 31, 2039

Study Completion Date

March 31, 2039

Conditions
Achondroplasia
Interventions
DRUG

TransCon CNP

TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

Trial Locations (15)

1023

Ascendis Investigational Site, Auckland

2100

Ascendis Pharma Investigational Site, Copenhagen

3052

Ascendis Pharma Investigational Site, Parkville

4020

Ascendis Investigational Site, Linz

13353

Ascendis Investigational Site, Berlin

14203

Ascendis Pharma Investigational Site, Buffalo

19803

Ascendis Investigational Site, Wilmington

53705

Ascendis Pharma Investigational Site, Madison

55102

Ascendis Investigational Site, Saint Paul

65212

Ascendis Pharma Investigational Site, Columbia Falls

72202

Ascendis Pharma Investigational Site, Little Rock

77030

Ascendis Investigational Site, Houston

80045

Ascendis Investigational Site, Aurora

D01 YC76

Ascendis Pharma Investigational Site, Dublin

3000-602

Ascendis Investigational Site, Coimbra

All Listed Sponsors
lead

Ascendis Pharma Growth Disorders A/S

INDUSTRY